Liquisolid technique for solubility enhancement of a poorly soluble thrombin inhibitor: optimization using design of experiments and artificial neural networks
DOI:
https://doi.org/10.56782/pps.340Keywords:
Liquisolid, design of experiments, D-optimal design, artificial neural networks, JMPAbstract
The current work uses liquisolid (LS) technology to increase the absorption efficiency and dissolution rate of the weakly water-soluble drug dabigatran etexilate (DE) by formulating it using the design of experiments (DoE) and comparing it with the artificial neural network (ANN). D-optimal design in Stat-Ease software was used to formulate and optimize DE liquisolid capsules. The drug-to-nonvolatile solvent ratio (X1 – 25 to 50), carrier-to-coating ratio (X2 – 10 to 30), type of nonvolatile solvent (X3 – PEG 400 or Kolliphor EL) and type of carrier (X4 – Neusilin or Fujicalin) were taken as independent variables and percentage drug release (Y1) and angle of repose (Y2) were taken as dependent variables. The results were compared to artificial neural networks (ANN) utilizing JMP software to improve the prediction of the chosen output variables. The optimized formulation was developed and evaluated. The R2 value of the D-optimal design for percentage drug release was 0.914, whereas for ANN, it was 0.943. The mean square error (MSE) value of the quadratic model obtained in the D-optimal design was 90.76, and in ANN, it was only 2.392. The R2 value for the quadratic model in the D-optimal design for the angle of repose was 0.723, whereas for ANN, it was 0.751. The MSE for the D‑optimal design was 28.11, whereas for ANN, it was 11.04. Based on the analysis of results, PEG400 was selected as the nonvolatile solvent and Neusilin as a carrier for optimized formulation. The percentage drug release and angle of repose of optimized DE liquisolid capsules were found to be 86.23 ± 1.37 and 36.08 ± 0.63, respectively. XRD studies indicated a reduction in the crystallinity of the drug in liquisolid formulations. The findings suggested that dabigatran etexilate's solubility rate could be increased by using liquisolid capsules. ANN gave better predictability than the design of experiments.
Downloads
References
1. Blair, H.A.; Keating, G.M. Dabigatran Etexilate: A review in nonvalvular atrial fibrillation. Drugs 2017, 77(3), 331-344. DOI: 10.1007/s40265-017-0699-z DOI: https://doi.org/10.1007/s40265-017-0699-z
2. Veenu, P.M.; Krutik,. K.S. Enhanced oral bioavailability and anticoagulant activity of dabigatran etexilate by self-micro emulsifying drug delivery system: systematic development, In vitro, Ex vivo and In vivo evaluation. J. Nanomed. Nanotechnol. 2018, 9(01), Art. No: 480. DOI: 10.4172/2157-7439.1000480 DOI: https://doi.org/10.4172/2157-7439.1000480
3. Ge, L.; He, X.; Zhang, Y; Chai, F.; Jiang, L.; Webster, T.J.; Zheng, C. A dabigatran etexilate phospholipid complex nanoemulsion system for further oral bioavailability by reducing drug-leakage in the gastrointestinal tract. Nanomedicine 2017, 30(17), 30156-30159. DOI: 10.1016/j.nano.2017.08.009 DOI: https://doi.org/10.1016/j.nano.2017.08.009
4. Hu, M.; Zhang, J; Ding, R.; Fu, Y; Gong, T.; Zhang, Z. Improved oral bioavailability and therapeutic efficacy of dabigatran etexilate via Soluplus-TPGS binary mixed micelles system. Drug Dev. Ind. Pharmy. 2017, 43(4), 687–697. DOI: 10.1080/03639045.2016.1278015 DOI: https://doi.org/10.1080/03639045.2016.1278015
5. Jagtap, S.; Magdum, C.; Jadge, D.; Jagtap, R. Solubility enhancement technique: a review. J. Pharm. Sci. Res. 2018, 10(9), 2205-2211.
6. Brahmankar, D.M.; Jaiswal, S.B. Biopharmaceutics and Pharmacokinetics: A Treatise. Vallabh Prakashan, Delhi, 2002.
7. Panda, S.; Varaprasad, R.; Priyanka, K.; Swain, R.P. Liquisolid technique: a novel approach for dosage form design. Int. J. Appl. Pharm. 2017, 9(3), Art. No: 8. DOI: 10.22159/ijap.2017v9i3.18698 DOI: https://doi.org/10.22159/ijap.2017v9i3.18698
8. Lu, M.; Xing, H.; Jiang, J.; Chen, X.; Yang, T.; Wang, D.; Ding, P. Liquisolid technique and its applications in pharmaceutics. Asian. J. Pharm. Sci. 2017, 12(2), 115-123. DOI: 10.1016/j.ajps.2016.09.007 DOI: https://doi.org/10.1016/j.ajps.2016.09.007
9. Kulkarni, A.; Alookar, N.; Mane, M.; Gaja, J. Liquisolid systems: a review. Int. J. Pharm. Sci. Nanotech. 2010, 3(1), 795-802. DOI: 10.37285/ijpsn.2010.3.1.1
10. Walke, P.S.; Pawar, A.Y.; Sonawane, D.D.; Bhamber, R.S. Liquisolid: a novel technique to enhance solubility and dissolution rate of BSC class II pharmaceuticals. J. Pharm Res. 2011, 4(11), 4011-4040. DOI: 10.24327/ijrsr.2022.1312.0562
11. Javadzadeh, Y.; Jafari-Navimipour, B.; Nokhodchi, A. Liquisolid technique for dissolution rate enhancement of a high dose water insoluble drug (carbamazepine). Int. J. Pharm. 2007, 341(1-2), 26-34. DOI: 10.1016/j.ijpharm.2007.03.034 DOI: https://doi.org/10.1016/j.ijpharm.2007.03.034
12. Prasanthi, D.; Priyanka, K. Formulation and evaluation of liquisolid compacts of Dabigatran Etexilate Mesylate. Indo Am. J. P. Sci. 2018, 05(01), 572-583. DOI: 10.5281/zenodo.1164135
13. Kulkarni, A.S.; Aloorkar, N.H.; Mane, M.S.; Gaja, J.B. Liquiosolid system: a review. Int. J. Pharm. Sci. Nanotechnol. 2010, 3(1), 795-802. DOI: 10.37285/ijpsn.2010.3.1.1 DOI: https://doi.org/10.37285/ijpsn.2010.3.1.1
14. Spireas, S.; Bolton, S. Sustained-release "liquisolid compacts". Proc. Int. Symp. Control. Rel. Bioact. Mater. 1998, 25, 138-139.
15. Patel, B.B.; Shah, C.N.; Shah, R.M.; Shah, D.P. Liquisolid technology: a novel approach to enhance solubility of poorly water soluble drugs. Res. J. Pharm. Technol. 2015, 8(12), 1733-1739. DOI: 10.5958/0974-360X.2015.00311.X DOI: https://doi.org/10.5958/0974-360X.2015.00311.X
16. Bhattacharya, S. Design and development of Docetaxel solid self-microemulsifying drug delivery system using principal component analysis and D-Optimal design. Asian J. Pharm. 2018, 12(01). DOI: 10.22377/ajp.v12i01.2051 DOI: https://doi.org/10.22377/ajp.v12i01.2051
17. Patel, D.S.; Pipaliya, R.M.; Surti, N. Liquisolid tablets for dissolution enhancement of a hypolipidemic drug. Indian J. Pharm. Sci. 2015, 77(3), 290-298 DOI: 10.4103/0250-474x.159618 DOI: https://doi.org/10.4103/0250-474X.159618
18. Rodriguez-Granrose, D.; Jones, A.; Loftus, H.; Tandeski, T.; Heaton, W.; Foley, K.T.; Silverman, L. Design of experiment (DOE) applied to artificial neural network architecture enables rapid bioprocess improvement. Bioprocess Biosyst. Eng. 2021, 44(6), 1301-1308. DOI: 10.1007/s00449-021-02529-3 DOI: https://doi.org/10.1007/s00449-021-02529-3
19. Olgac, A.; Karlik, B. Performance analysis of various activation functions in generalized MLP architectures of neural networks. Int. J. Artif. Intell. Expert Syst. 2011, 1, 111–122.
20. Baharin, A.; Abdullah, A.; Yousof, S.N.M. Prediction of bioprocess production using deep neural network method. Telkomnika 2017, 15, 805–813. DOI: https://doi.org/10.12928/telkomnika.v15i1.6124
21. Elkordy, A.A; Tan, X.N; Essa, E.A. Spironolactone release from liquisolid formulations prepared with Capryol™ 90, Solutol® HS-15 and Kollicoat® SR 30 D as non-volatile liquid vehicles. Eur. J. Pharm. Biopharm. 2013, 83(2), 203-223. DOI: 10.1016/j.ejpb.2012.08.004 DOI: https://doi.org/10.1016/j.ejpb.2012.08.004
22. Tayel, S.A; Soliman, II.; Louis, D. Improvement of dissolution properties of carbamazepine through application of the liquisolid tablet technique. Eur. J. Pharm. Biopharm. 2008, 69, 342–347. DOI: 10.1016/j.ejpb.2007.09.003 DOI: https://doi.org/10.1016/j.ejpb.2007.09.003
23. Salunkhe, A.; Yadav, A.; Adhikrao; Sakhare, S.; Doijad, R.; Shete, A. Neusilin based liquisolid compacts of albendazole: design, development, characterization and in vitro anthelmintic activity. J. Res. Pharm. 2019, 23(3), 441-456. DOI: 10.12991/jrp.2019.151 DOI: https://doi.org/10.12991/jrp.2019.151
24. Vinod Valjibhai Siju, Moinuddin Soniwala. Liquisolid compact: A new technology for optimization of paliperidone tablets by central composite design. Int. J. Pharm. Sci. Rev. 2017, 45(1), 11-17.
25. Fahmy, R.H.; Kassem, M.A. Enhancement of famotidine dissolution rate through liquisolid tablets formulation: in vitro and in vivo evaluation. Eur. J. Pharm. Biopharm. 2008, 69(3), 993-1003. DOI: 10.1016/j.ejpb.2008.02.017 DOI: https://doi.org/10.1016/j.ejpb.2008.02.017
26. Burra, S.; Yamsani, M.; Vobalaboina, V. The Liquisolid technique: an overview. Brazilian J. Pharm. Sci. 2011, 47(3), 475–482. DOI: 10.1590/S1984-82502011000300005 DOI: https://doi.org/10.1590/S1984-82502011000300005
28. Hentzschel, C.M.; Sakmann, A.; Leopold, C.S. Suitability of various excipients as carrier and coating materials for liquisolid compacts. Drug Dev. Ind. Pharm. 2011, 37(10), 1200–1207. DOI: 10.3109/03639045.2011.564184 DOI: https://doi.org/10.3109/03639045.2011.564184
29. Spireas, S. Liquisolid systems and methods of preparing same. 2002, U.S Patent 6423339B1.
30. Prajapati, S.T.; Bulchandani, H.H.; Patel, D.M.; Dumaniya, S.K.; Patel, C.N. Formulation and evaluation of liquisolid compacts for olmesartan medoxomil. J. Drug Del. 2013, 2013, Art. No: 870579. DOI: 10.1155/2013/870579 DOI: https://doi.org/10.1155/2013/870579
31. Valaei, I.; Hassan-Beygi, S.R.; Kianmehr, M.H.; Massah, J. Investigation of avalanche time and Carr’s index of poultry litter powder as flowability indices. Cercetari Agronomice in Moldova. 2012, XIV, 4(152), 15–27. DOI: 10.2478/v10298-012-0061-2 DOI: https://doi.org/10.2478/v10298-012-0061-2
32. Brown, C.K.; Friedel, H.D.; Barker, A.R.; Buhse, L.F.; Keitel, S.; Cecil, T.L.; Kraemer, J; Morris, J.M.; Reppas, C.; Stickelmeyer, M.P.; Yomota, C; Shah, V.P. FIP/AAPS joint workshop report: dissolution/in vitro release testing of novel/special dosage forms. AAPS PharmSciTech. 2011, 12(2), 782-94. DOI: 10.1208/s12249-011-9634-x DOI: https://doi.org/10.1208/s12249-011-9634-x
33. Chella, N.; Shastri, N.; Tadikonda, R.R. Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharm. Sinica B. 2012, 2(5), 502–508. DOI: 10.1016/j.apsb.2012.07.005 DOI: https://doi.org/10.1016/j.apsb.2012.07.005
34. Aghajanpour, S.; Yousefi Jordehi, S.; Farmoudeh, A.; et al. Applying liquisolid technique to enhance curcumin solubility: a central composite design study. Chem. Pap. 2024, 78, 9257–9271. DOI: 10.1007/s11696-024-03741-7 DOI: https://doi.org/10.1007/s11696-024-03741-7
35. Dhanaraju; M. D.; Devendiran; S.; Vadaga; A.; Ramya; N. Formulation and optimization of liquisolid compact of Atazanavir by using DoE approach. Eur. J. Pharm. 2023, 12, 53-66. DOI: 10.48047/ecb/2023.12.si11.0032023.15/07/2023
36. Saini, L.M.; Soni, M.K. Artificial neural network based peak load forecasting using levenberg–marquardt and quasi-newton methods. IEE Proceedings - Generation, Transmission and distribution. 2002, 149(5), 578. DOI: 10.1049/ip-gtd:20020462 DOI: https://doi.org/10.1049/ip-gtd:20020462
37. Mourabet, M.; Abdelhadi; El Rhilassi, l.; Bennani-Ziatni, M.; Taitai, A.. Comparative study of artificial neural network and response surface methodology for modelling and optimization the adsorption capacity of fluoride onto apatitic tricalcium phosphate. Univers. J. Appl. Math. 2014, 2(2), 84-91. DOI: 10.13189/ujam.2014.020202. DOI: https://doi.org/10.13189/ujam.2014.020202
38. Sari, D.W.; Wardhana, Y.W.; Rusdiana, T. Enhancement of solubility BCS class II and IV pharmaceuticals by liqusolid technique: A review. Indo. J. Pharm. 2020, 2(2), 77-88. DOI: 10.24198/idjp.v2i2.27297 DOI: https://doi.org/10.24198/idjp.v2i2.27297
39. Amrani, F.; Secretan, P.-H.; Sadou-Yayé, H.; Aymes-Chodur, C.; Bernard, M.; Solgadi, A.; Yagoubi, N.; Do, B. Identification of dabigatran etexilate major degradation pathways by liquid chromatography coupled to multi stage high-resolution mass spectrometry. RSC Adv. 2015, 5, 45068-45081. DOI: 10.1039/C5RA04251H. DOI: https://doi.org/10.1039/C5RA04251H
40. Korni, R.D.; Gonugunta, C.S. Olanzapine liquisolid tablets using Kolliphor EL with improved flowability and bioavailability: In vitro and In vivo characterization. Turkish J. Pharm. Sci. 2024, 21(1), 52-61. DOI: https://doi.org/10.4274/tjps.galenos.2023.05752
41. Jaydip, B.; Dhaval, M.; Soniwala, M.M.; Chavda, J. Formulation and optimization of liquisolid compact for enhancing dissolution properties of efavirenz by using DoE approach. Saudi Pharm. J. 2020, 28(6), 737-745. DOI: 10.1016/j.jsps.2020.04.016 DOI: https://doi.org/10.1016/j.jsps.2020.04.016
42. Korni, R.; Voodikala, S.; Gonugunta, C.S.; Jayanti, V. Liquisolid technique: An approach to enhance the dissolution rate of Olanzapine. Indian J. Pharm. Sci. 2018, 80(6), 1003-1010. DOI: https://doi.org/10.4172/pharmaceutical-sciences.1000450
43. Shah, P.; Desai, H.; Vyas, B.; Lalan, M.; Kulkarni, M. Quality-by-design-based development of Rivaroxaban-loaded liquisolid compact tablets with improved biopharmaceutical attributes. AAPS PharmSciTech. 2023, 24, Art. No: 176. DOI: 10.1208/s12249-023-02635-3 DOI: https://doi.org/10.1208/s12249-023-02635-3
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Rama Devi Korni, Thanmaisree Bora, Akhil Majji, Jagadeesh Panda
This work is licensed under a Creative Commons Attribution 4.0 International License.
For all articles published in Prospects in Pharmaceutical Sciences copyright is retained by the authors. The journal publishes articles in the Open Access policy, within the CC BY 4.0 licence.
This is a human-readable summary of (and not a substitute for) the license. Disclaimer.
You are free to:
Share — copy and redistribute the material in any medium or format
Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
How to Cite
